Hematologic Malignancy
T-Cell and NK-Cell Neoplasm
CI-CAN-00001561Explore in graph →
HematologicNon-malignant268 active trials13 approved drugs18 evidence items
- NCIt
- C27908
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00001561Explore in graph →
Clinical trials
1,103 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05476770 | Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | recruiting | Phase 1 | 54 | Therapeutic Advances in Childhood Leukemia ConsortiumOTHER | 2 | Dec 6, 2024 | clinicaltrials |
| NCT05886478 | A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin | completed | — | 26 | TakedaINDUSTRY | 4 | Dec 4, 2024 | clinicaltrials |
| NCT01919619 | Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | completed | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT06712173 | Linperlisib Combined With EZH2 Inhibitor in Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) | not yet recruiting | Phase 1 | 33 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Dec 2, 2024 | clinicaltrials |
| NCT06701344 | Go-CHOP in de Novo Intestinal T-cell Lymphoma Patients(GOAL) | not yet recruiting | Phase 2 | 7 | Ruijin HospitalOTHER | 0 | Nov 22, 2024 | clinicaltrials |
| NCT05333367 | MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy(MORPHEE) | recruiting | N/A | 20 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05509855 | A Long-Term Safety Follow-Up Study for Patients Treat With WU-CART-007 | enrolling by invitation | — | 44 | Allotera TherapeuticsINDUSTRY | 2 | Nov 20, 2024 | clinicaltrials |
| NCT04840875 | Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma | completed | Phase 1 | 16 | Beijing Boren HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05032599 | Donor-Derived CD5 CAR T Cells in Subjects with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia | terminated | Phase 1 | 19 | Beijing Boren HospitalOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT05269940 | A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies | completed | Phase 1 / Phase 2 | 40 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Nov 13, 2024 | clinicaltrials |
| NCT06420076 | Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells(BAH246) | recruiting | Phase 1 / Phase 2 | 60 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT05260203 | MargheRITA (Remote Intelligence for Therapeutic Adherence)(MargheRITA) | completed | N/A | 124 | Advice Pharma Group srlINDUSTRY | 1 | Nov 6, 2024 | clinicaltrials |
| NCT06671717 | Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma | not yet recruiting | N/A | 25 | Peking University People's HospitalOTHER | 1 | Nov 6, 2024 | clinicaltrials |
| NCT04101331 | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides(REDIRECT) | completed | Phase 2 | 108 | Affimed GmbHINDUSTRY | 10 | Nov 5, 2024 | clinicaltrials |
| NCT03586999 | Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas | completed | Phase 1 / Phase 2 | 18 | University of Colorado, DenverOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06176027 | Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas | recruiting | Phase 1 / Phase 2 | 52 | Navy General Hospital, BeijingOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03493451 | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | completed | Phase 2 | 77 | BeiGeneINDUSTRY | 5 | Oct 26, 2024 | clinicaltrials |
| NCT05662540 | PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma | recruiting | N/A | 40 | Ruijin HospitalOTHER | 1 | Oct 26, 2024 | clinicaltrials |
| NCT06651203 | Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study(KISS01) | not yet recruiting | — | 460 | Assistance Publique - Hôpitaux de ParisOTHER | 0 | Oct 21, 2024 | clinicaltrials |
| NCT03989466 | Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia | completed | Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06633341 | Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma | recruiting | Early Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06633354 | Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-ALL | recruiting | Early Phase 1 | 30 | Zhejiang UniversityOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT06598722 | BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma. | recruiting | Phase 2 | 206 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT01460914 | Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment | completed | — | 34 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 20, 2024 | clinicaltrials |
| NCT02953652 | Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | completed | Phase 2 | 55 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT02953301 | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)(RESMAIN) | completed | Phase 2 | 201 | 4SC AGINDUSTRY | 12 | Aug 30, 2024 | clinicaltrials |
| NCT06550336 | A Clinical Study Assessing the Efficacy of Chidamide for CD30-positive Peripheral T-cell Lymphoma (PTCL). | active not recruiting | Phase 2 | 35 | The First Hospital of Jilin UniversityOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT06573138 | Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL | not yet recruiting | Phase 2 | 18 | Ruijin HospitalOTHER | 0 | Aug 27, 2024 | clinicaltrials |
| NCT01793233 | Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas | completed | — | 203 | Children's Oncology GroupNETWORK | 2 | Aug 26, 2024 | clinicaltrials |
| NCT04676087 | Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 5 | Emory UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06548347 | A Phase II/III Study of Linperlisib Plus CHOP Versus CHOP in Patients With Newly Diagnosed Peripheral T Cell Lymphoma | not yet recruiting | Phase 2 / Phase 3 | 606 | Shanghai YingLi Pharmaceutical Co. Ltd.INDUSTRY | 0 | Aug 12, 2024 | clinicaltrials |
| NCT02192021 | Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)(MNA-D) | completed | Phase 1 | 20 | Falo, Louis, MDOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05749549 | Phase I/IIa Study of BR1733 in Subjects With Advanced Cancers | unknown | Phase 1 / Phase 2 | 191 | Shanghai Blueray Biopharma Co., Ltd.INDUSTRY | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06468267 | RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. | unknown | Phase 2 | 50 | Xianmin Song, MDOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06509945 | Allo-PBSCT as the First-line Treatment for Patients With the High-risk PTCL | unknown | N/A | 50 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT02576496 | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 | 106 | Mundipharma Research LimitedINDUSTRY | 7 | Jul 25, 2024 | clinicaltrials |
| NCT04014374 | Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab | recruiting | — | 150 | Kyowa Kirin, Inc.INDUSTRY | 1 | Jul 24, 2024 | clinicaltrials |
| NCT00557193 | Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 3 | 218 | Children's Oncology GroupNETWORK | 4 | Jul 15, 2024 | clinicaltrials |
| NCT06494371 | A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma | recruiting | Phase 1 | 32 | Ruijin HospitalOTHER | 1 | Jul 10, 2024 | clinicaltrials |
| NCT06492629 | Toripalimab Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma | unknown | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2024 | clinicaltrials |
| NCT05105412 | Lenalidomide and Gemcitabine in Relapsed or Refractory Peripheral T-cell Lymphomas | terminated | Phase 1 / Phase 2 | 12 | National Health Research Institutes, TaiwanOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT03217643 | CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.(EATL-001) | completed | Phase 2 | 14 | Imagine InstituteOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT01611142 | Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) | completed | Phase 2 | 38 | Kyowa Kirin Co., Ltd.INDUSTRY | 6 | Jun 17, 2024 | clinicaltrials |
| NCT00341939 | Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data | completed | — | 484 | National Cancer Institute (NCI)NIH | 1 | Jun 13, 2024 | clinicaltrials |
| NCT03061188 | Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma | completed | Phase 1 | 15 | Northwestern UniversityOTHER | 1 | Jun 12, 2024 | clinicaltrials |
| NCT01716806 | A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) | completed | Phase 2 | 131 | Seagen Inc.INDUSTRY | 2 | Jun 11, 2024 | clinicaltrials |
| NCT06436677 | A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma(AMITY) | recruiting | — | 100 | Peking University First HospitalOTHER | 1 | May 31, 2024 | clinicaltrials |
| NCT06434467 | The Efficacy and Safety of Nelarabine Injection in Patients With T-lymphoblastic Leukemia and T-lymphoblastic Lymphoma | unknown | Phase 3 | 83 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | May 30, 2024 | clinicaltrials |
| NCT06433362 | CMOEP in the Treatment of Untreated Peripheral T-cell Lymphoma | unknown | Phase 2 | 115 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 29, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Dec 6, 2024source: clinicaltrials